Dabigatran (ethyl ester)

Dabigatran ethyl ester is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity. IC50 value: Target: thrombin Dabigatran provides a stable anticoagulation effect without any need to perform periodical laboratory controls. Of note, there is a growing amount of clinical evidence which shows its safety and efficacy. For these reasons, Dabigatran may suppose a revolution in oral anticoagulation. Dabigatran etexilate was rapidly converted to Dabigatran, with peak plasma dabigatran concentrations being attained after approximately 1.5 h; the bioavailability of Dabigatran after p.o. administration of Dabigatran etexilate was 7.2%.

Product Specifications

CAS Number

[429658-95-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Thrombin

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/dabigatran-ethyl-ester.html

Purity

99.02

Solubility

DMSO : 75 mg/mL (ultrasonic)

Smiles

O=C(N(C1=NC=CC=C1)CCC(OCC)=O)C2=CC=C3C(N=C(N3C)CNC4=CC=C(C(N)=N)C=C4)=C2

Molecular Formula

C27H29N7O3

Molecular Weight

499.56

Precautions

H302, H315, H319, H335

References & Citations

[1]Simon Michaelis, Anett Marais, Anna K. Schrey, et al. Dabigatran and Dabigatran Ethyl Ester: Potent Inhibitors of Ribosyldihydronicotinamide Dehydrogenase (NQO2) . J. Med. Chem., 2012, 55 (8) :3934-3944|[2]Preetpal Singh Sidhu, Aiye Liang, Akul Y. Mehta, et al. Rational Design of Potent, Small, Synthetic Allosteric Inhibitors of Thrombin. J Med Chem. 2011; 54 (15) : 5522-5531.|[3]Santiago Redondo, Maria-Paz Martínez, Marta Ramajo, et al. Pharmacological basis and clinical evidence of dabigatran therapy. J Hematol Oncol. 2011; 4: 53.|[4]Stefan Blech, Thomas Ebner, Eva Ludwig-Schwellinger, et al. The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans. DMD ,2008 , 36 (2) 386-399|[5]Dabigatran